PL3505512T3 - Pochodne soli pirydyniowych jako prekursory do uwalniania MNA - Google Patents

Pochodne soli pirydyniowych jako prekursory do uwalniania MNA

Info

Publication number
PL3505512T3
PL3505512T3 PL18248109.3T PL18248109T PL3505512T3 PL 3505512 T3 PL3505512 T3 PL 3505512T3 PL 18248109 T PL18248109 T PL 18248109T PL 3505512 T3 PL3505512 T3 PL 3505512T3
Authority
PL
Poland
Prior art keywords
derviatives
mna
nicotinamide
precursors
quaternary
Prior art date
Application number
PL18248109.3T
Other languages
English (en)
Inventor
Stefan CHŁOPICKI
Kamil Kuś
Ivars Kalvins
Victor Adrianov
Einars Loza
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Publication of PL3505512T3 publication Critical patent/PL3505512T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18248109.3T 2017-12-31 2018-12-28 Pochodne soli pirydyniowych jako prekursory do uwalniania MNA PL3505512T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie

Publications (1)

Publication Number Publication Date
PL3505512T3 true PL3505512T3 (pl) 2022-07-25

Family

ID=65493778

Family Applications (2)

Application Number Title Priority Date Filing Date
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie
PL18248109.3T PL3505512T3 (pl) 2017-12-31 2018-12-28 Pochodne soli pirydyniowych jako prekursory do uwalniania MNA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie

Country Status (2)

Country Link
EP (1) EP3505512B1 (pl)
PL (2) PL238932B1 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) * 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
PL364348A1 (pl) * 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
US20110082177A1 (en) * 2008-07-01 2011-04-07 Jerzy Gebicki N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
JP6621329B2 (ja) * 2012-10-05 2019-12-18 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用

Also Published As

Publication number Publication date
EP3505512A1 (en) 2019-07-03
PL238932B1 (pl) 2021-10-18
PL424073A1 (pl) 2019-07-01
EP3505512B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
IL280485A (en) Sustained-release pridopidine preparations
GB2588505B (en) Preparation of psilocybin
PL3328867T3 (pl) Krystaliczna postać wolnej zasady lorlatynibu
HUE064651T2 (hu) A bedaquilin késleltetett hatású formulái
PL3474822T3 (pl) Preparaty brincydofowiru
IL268835B (en) A process for the preparation of 2-cyanoimidazole compounds
IL266683A (en) Precursors for radiofluorination reactions
SG11201803156TA (en) Sustained release formulations of local anesthetics
SMT202200202T1 (it) Sali e polimorfi innovativi di scy-078
PL3110249T3 (pl) Sposób wytwarzania mikrokapsułek biobójczych
GB201609314D0 (en) Methods of forming compounds
IL263673A (en) Solid state forms of spiro-oxindole compounds
IL275480A (en) A process for the preparation of pyrimidinyl-4-aminopyrazole compounds
IL271233A (en) Quinolinicyclohexylpropanamide-modified compounds and improved methods for their preparation
ZA201701063B (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
ZA202002116B (en) Process for the preparation of piperine
IL248139A0 (en) Preparation of microelectrodes
PL3505512T3 (pl) Pochodne soli pirydyniowych jako prekursory do uwalniania MNA
PT3412667T (pt) Cocristal
IL263363A (en) Polymorph of nintedanib
GB201520346D0 (en) Stable amorphous form of daclatasvir
PT3393246T (pt) Processo para a preparação de um agente quelante
AU2015903141A0 (en) Controlled release formulations of paracetamol
HK1228789A1 (en) Modified release formulations of pridopidine